- PR Newswire•5 hours ago
The objective of the study was to validate the in vitro capture of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. The Company also reported that it conducted a related study to identify the presence of each of these viruses in blood samples obtained from organ transplant patients who were also suffering from sepsis.
- Zacks Small Cap Research•7 days ago
Aethlon (AEMD) reported financial results for their fiscal third quarter 2017 (ending December 2016) and provided an operational update. There were no meaningful surprises in the financial results relative to our expectations with the top-line ($0 A vs. $8k E), operating expenses ($1.2M A vs. $1.3M E), net loss ($1.2M A vs. $1.3M E) and EPS (-$0.15 A vs. -$0.16) E) all coming in just about exactly where we had modeled. Relative to the balance sheet, AEMD exited fiscal Q3 with $628k cash and equivalents. They raised $288k and $578k (net) from the sale of equity (via ATM) and convertible notes, respectively, during the quarter. Subsequent to quarter-end, AEMD raised an additional $256k (net) via the sale of 64k common shares @ $3.98/share average through their ATM program. Aethlon raised ~$810k through the ATM program since the beginning of Q2 and there remains ~$11M still available.
- PR Newswire•12 days ago
SAN DIEGO, Feb. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal ...
AEMD : Summary for AETHLON MEDICAL INC - Yahoo Finance
Aethlon Medical, Inc. (AEMD)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||3.82 x 1000|
|Ask||3.93 x 100|
|Day's Range||3.80 - 4.22|
|52 Week Range||3.55 - 9.09|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.43|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|